Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2013, Article ID 792526, 4 pages
Case Report

The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis

1Department of Rheumatology, Faculty of Medicine, Şifa University, Bornova, 35100 Izmir, Turkey
2Department of Orthopaedic Surgery, Faculty of Medicine, Şifa University, Bornova, 35100 Izmir, Turkey
3Department of Rheumatology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey

Received 19 August 2013; Accepted 30 September 2013

Academic Editors: M. Salazar-Paramo, G. J. Tsay, and A. Zoli

Copyright © 2013 Şenol Kobak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Rheumatoid arthritis (RA) is considered as a connective tissue disease while ankylosing spondylitis (AS) is a prototype of spondyloarthritis. These diseases are seen concomitantly only very rarely. Also, rituximab has proven efficacy in the treatment of RA while its role in the treatment of AS is unclear. In this presentation, the concomitant presence of RA and AS in a 43-year-old male patient as well as the efficacy and safety of rituximab is discussed. Rituximab was given due to lack of response to treatment with anti-TNF-alpha. Evaluations made at the 6th and 12th months of treatment showed complete response for RA and partial response for AS.